DOCSLIB.ORG

WO 2014/145352 Al 18 September 2014 (18.09.2014) P O P C T

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WO 2014/145352 Al 18 September 2014 (18.09.2014) P O P C T (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/145352 Al 18 September 2014 (18.09.2014) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, C02F 3/06 (2006.01) C02F 9/12 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, C02F 9/08 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (21) International Application Number: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PCT/US20 14/030094 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (22) International Filing Date: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, 16 March 2014 (16.03.2014) TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, 61/788,206 15 March 2013 (15.03.2013) US UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (71) Applicant: SUBTECH INDUSTRIES LLC [FJ/US]; PO EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, Box 1226, Stuart, FL 34995 (US). MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (72) Inventors: SANCHEZ, David; 2734 Se Eagle Drive, Port KM, ML, MR, NE, SN, TD, TG). Saint Lucie, FL 34984 (US). DEWEERDT, Leonard; 1418 San Esteban Ave., Port Saint Lucie, FL 34953 (US). Published: (74) Agent: KELLER, Michael; Keller Life Science Law PA, — with international search report (Art. 21(3)) PO Box 969, Pompano Beach, FL 33061-0969 (US). — before the expiration of the time limit for amending the (81) Designated States (unless otherwise indicated, for every claims and to be republished in the event of receipt of kind of national protection available): AE, AG, AL, AM, amendments (Rule 48.2(h)) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (54) Title: WATER WITH IMPROVED TRANSDERMAL AND CELLULAR DELIVERY (57) Abstract: A process for preparing conventional water sources for providing ideal state cellular wellness benefits via topical hy dration and natural transdermal, epithelial or epicellular absorption. The invention's process considers preconditioned water sources o that have removed solids, dissolved solids, contaminants - both organic and inorganic and subsequently the method purifies the wa ter respective of removing pathogens, and structures the water for cellular uptake in the form of vicinal grade water, with improved characteristics of ideal frequency, cluster size, pH, before safely introducing negative ORP (highly ionized state) to the water struc - o ture and organic nutrients or other supplemental pharmaceutical grade organic materials onto the skin or epithelial/epi-cellular envir onments surrounding tissue and cells. WATER WITH IMPROVED TRANSDERMAL AND CELLULAR DELIVERY Incorporation by Reference and Claim of Priority [001] This application claims priority to United States provisional patent application number 61/788,206 filed on March 15, 2013, the contents of which are expressly incorporated by reference. The contents of all references cited herein are expressly incorporated in their entirety. Background of the Invention [002] Water is ubiquitous in biology and plays roles which are well known and many which we do not fully appreciate. Water plays a primary role in biology for solubilizing and transporting molecules required to maintain life. The art primarily teaches ingestion of water solubilized molecules to meet nutritional or therapeutic needs. [003] Water is universally recognized as a good solvent for charged and polar solvents and a poor solvent for hydrocarbons. [004] The art has recognized that intracellular water, water located within cells, appears to be different than water as we generally know it in normal bulk phase. Phillipa Wiggins, Role of Water in Some Biological Processes, Microbiological Reviews. Vol 54 (4) p432- 449 (1990). In fact, there appears to be 3 forms of water, water which is bound to surfaces, vicinal water associate with surfaces but not bound to them and ordinary aqueous water. Each of these three forms has different properties. [005] In recent years the literature has given greater attention to vicinal water and its role in cellular function. [006] Many enzymatic reactions are oxidation-reduction reactions in which one compound is oxidized and another compound is reduced. The ability of an organism to carry out oxidation-reduction reactions depends on the oxidation-reduction state of the environment, or its reduction potential. [007] In aqueous solutions, the reduction potential is a measure of the tendency of the solution to either gain or lose electrons when it is subject to change by introduction of a new species. A solution with a higher (more positive) reduction potential than the new species will have a tendency to gain electrons from the new species (i.e. to be reduced by oxidizing the new species) and a solution with a lower (more negative) reduction potential will have a tendency to lose electrons to the new species (i.e. to be oxidized by reducing the new species). Oxidation Reduction Potential ("ORP") is generally measured by means of a electrode. Redox meters are well known in the art. [008] However, internal delivery of molecules is not always efficient or even effective due to the many mechanisms the body has to prevent contamination including but not limited to filtering by liver and kidneys and active pumps present in the gut such as p glycoprotein. [009] The art has tried to create ways to improve the properties of water for various biological purposes. Various attempts have been made to produce structured water through electrochemical cells or filtration media. [010] Below are representative patents and published patent applications relevant to structured water. [01 1] JP 20044285036 for Skin Conditioning Agent to Hiroshima Kasei. This application teaches a skin conditioning agent which is produced electrolytically containing a reduced water having a neutral pH and a negative 400 redox. [012] JP 2006096667 and US 5776346 teach that water produced by ion exchange resins including tourmaline and aluminum oxide having negative oxidation reduction potential is ingestible to lower blood sugar. [013] JP2006326374 teaches the use of electrodes to modify the redox potential of water along with use of tourmaline. [014] JP2003335655A2 discloses a mineral water generated by passing natural water through a column that includes tourmaline. No values appear to be given for redox. [015] US 200401 18775 A l teaches the use of bubbling hydrogen gas through water to produce a product with a ph from 6.5-9 and redox values from -150 to -900. [016] US 5880048 A for Granular Ceramic for Water Deoxidation and method of Producing the same Sato; Kazuo et al. [017] KR100647036B1 for Filter for Generating Alkaline Reduced Water and Apparatus Using the Same to Jeon Hyoung Tag. This patent discloses the use of ORP balls but does not appear to reach the negative redox levels you achieve (no English language version available) [0 18] US20120213756A1 teaches the use of oral fulvic acid to scavenge free radicals and transport nutrients. It does not teach transdermal use. [019] US2006/7067155 Anti-inflammatory humate compositions and methods of use thereof teaches the use of humates and fulvics as supplementation that can reduce inflammation. [020] Phytochemicals and micronutrients sourced from plants are now known to impact gene expression in animals according to recent studies. Cell Research 22:3-5, doi:1038/cr.201 1.164;published online October 201 1 article entitled "Ingested plant miRNAs regulate gene expression in animals" clearly showed phenotypical changes related to proteomic influences in animals tested. [021] US20 10/0092399 A l for Methods of Treating or Preventing Inflammation and Hypersensitivity with Oxidative Reduction Potential Water Solution to Hojabr Alimi. This published patent application teaches the use of high positive ORP water generated electrolytically. [022] US20 10/03 16776 for Compositions and Methods for Producing Stable Negative ORP in Consumable Materials to Dusan Miljkovic. This published patent application teaches using reducing compounds to generate high negative ORP water. KHC03 is primarily used and ascorbic acid used to adjust pH. [023] US 2006/0275498 for Processed Water and Therapeutic Uses Thereof to David Bagley discloses the use of electrolytically obtained negative ORP water to treat conditions. [024] US 571 1950 and 6033678 teach the preparation of microclustered water using steam, magnetic fields and far infra-red to ultraviolet spectrum range light. [025] US 7,291,314 for Activated water apparatus and methods teaches a structured water having an ORP below -350 and a cluster size below 4 and a pH below 4 or higher than 10 produced via RD plasma. [026] In a recent study, fungal activity was altered by water borne frequency; refer to patent WO2007068831 (A2) — 2007-06-21, Luc Montagnier, METHOD FOR CHARACTERISING A BIOLOGICALLY ACTIVE BIOCHEMICAL ELEMENT BY ANALYSING LOW FREQUENCY ELECTROMAGNETIC SIGNALS Electromagnetic field frequency memory in water as revealed by germination responses of fungal spores O. E. Ehinlafaa*, G. A. Ibitolab and O. Okunyec a Department of Physics, University of Ilorin, Ilorin, Nigeria [027] It is recognized that providing ionized water orally encourages free radical (toxin) removal both extra cellularly and intra-cellularly.
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,101,662 B2 Tamarkin Et Al
    USOO91 01662B2 (12) United States Patent (10) Patent No.: US 9,101,662 B2 Tamarkin et al. (45) Date of Patent: *Aug. 11, 2015 (54) COMPOSITIONS WITH MODULATING A61K 47/32 (2013.01); A61 K9/0014 (2013.01); AGENTS A61 K9/0031 (2013.01); A61 K9/0034 (2013.01); A61 K9/0043 (2013.01); A61 K (71) Applicant: Foamix Pharmaceuticals Ltd., Rehovot 9/0046 (2013.01); A61 K9/0048 (2013.01); (IL) A61 K9/0056 (2013.01) (72) Inventors: Dov Tamarkin, Macabim (IL); Meir (58) Field of Classification Search Eini, Ness Ziona (IL); Doron Friedman, CPC ........................................................ A61 K9/12 Karmei Yosef (IL); Tal Berman, Rishon See application file for complete search history. le Ziyyon (IL); David Schuz, Gimzu (IL) (56) References Cited (73) Assignee: Foamix Pharmaceuticals Ltd., Rehovot U.S. PATENT DOCUMENTS (IL) 1,159,250 A 11/1915 Moulton (*) Notice: Subject to any disclaimer, the term of this 1,666,684 A 4, 1928 Carstens patent is extended or adjusted under 35 1924,972 A 8, 1933 Beckert 2,085,733. A T. 1937 Bird U.S.C. 154(b) by 0 days. 2,390,921 A 12, 1945 Clark This patent is Subject to a terminal dis 2,524,590 A 10, 1950 Boe claimer. 2,586.287 A 2/1952 Apperson 2,617,754 A 1 1/1952 Neely 2,767,712 A 10, 1956 Waterman (21) Appl. No.: 14/045,528 2.968,628 A 1/1961 Reed 3,004,894 A 10/1961 Johnson et al. (22) Filed: Oct. 3, 2013 3,062,715 A 11/1962 Reese et al.
    [Show full text]
  • Pharmaceutical and Veterinary Compounds and Metabolites
    PHARMACEUTICAL AND VETERINARY COMPOUNDS AND METABOLITES High quality reference materials for analytical testing of pharmaceutical and veterinary compounds and metabolites. lgcstandards.com/drehrenstorfer dr.ehrenstorfer@lgcgroup.com LGC Quality | ISO 17034 | ISO/IEC 17025 | ISO 9001 PHARMACEUTICAL AND VETERINARY COMPOUNDS AND METABOLITES What you need to know Pharmaceutical and veterinary medicines are essential for To facilitate the fair trade of food, and to ensure a consistent human and animal welfare, but their use can leave residues and evidence-based approach to consumer protection across in both the food chain and the environment. In a 2019 survey the globe, the Codex Alimentarius Commission (“Codex”) was of EU member states, the European Food Safety Authority established in 1963. Codex is a joint agency of the FAO (Food (EFSA) found that the number one food safety concern was and Agriculture Office of the United Nations) and the WHO the misuse of antibiotics, hormones and steroids in farm (World Health Organisation). It is responsible for producing animals. This is, in part, related to the issue of growing antibiotic and maintaining the Codex Alimentarius: a compendium of resistance in humans as a result of their potential overuse in standards, guidelines and codes of practice relating to food animals. This level of concern and increasing awareness of safety. The legal framework for the authorisation, distribution the risks associated with veterinary residues entering the food and control of Veterinary Medicinal Products (VMPs) varies chain has led to many regulatory bodies increasing surveillance from country to country, but certain common principles activities for pharmaceutical and veterinary residues in food and apply which are described in the Codex guidelines.
    [Show full text]
  • Performance-Based Test Guideline for Stably Transfected Transactivation in Vitro Assays to Detect Estrogen Receptor Agonists and Antagonists
    OECD/OCDE 455 Adopted: XXX OECD GUIDELINE FOR THE TESTING OF CHEMICALS Draft Performance-Based Test Guideline for Stably Transfected Transactivation In Vitro Assays to Detect Estrogen Receptor Agonists and Antagonists GENERAL INTRODUCTION Performance-Based Test Guideline 1. This Performance-Based Test Guideline (PBTG) describes the methodology of Stably Transfected Transactivation In Vitro Assays to detect Estrogen Receptor Agonists and Antagonists (ER TA assays). It comprises several mechanistically and functionally similar test methods for the identification of estrogen receptor (i.e, ER, and/or ER) agonists and antagonists and should facilitate the development of new similar or modified test methods in accordance with the principles for validation set forth in the OECD Guidance Document (GD) on the Validation and International Acceptance of New or Updated Test Methods for Hazard Assessment (1). The fully validated reference test methods (Annex 2 and Annex 3) that provide the basis for this PBTG are: The Stably Transfected TA (STTA) assay (2) using the (h) ERα-HeLa-9903 cell line; and The BG1Luc ER TA assay (3) using the BG1Luc-4E2 cell line which predominately expresses hERα with some contribution from hER(4) (5). Performance standards (PS) (6) (7) are available to facilitate the development and validation of similar test methods for the same hazard endpoint and allow for timely amendment of this PBTG so that new similar test methods can be added to an updated PBTG; however, similar test methods will only be added after review and agreement that performance standards are met. The test methods included in this Test Guideline can be used indiscriminately to address countries’ requirements for test results on estrogen receptor transactivation while benefiting from the Mutual Acceptance of Data.
    [Show full text]
  • In Vitro Characterization of the Novel Solubilizing Excipient Soluplus
    In vitro characterization of the novel solubility enhancing excipient Soluplus⃝R DISSERTATION zur Erlangung des Grades des Doktors der Naturwissenschaften der Naturwissenschaftlich-Technischen Fakultät III Chemie, Pharmazie, Bio- und Werkstoffwissenschaften der Universität des Saarlandes von Michael Linn Saarbrücken 2011 Tag des Kolloquiums: 19. Dezember 2011 Dekan: Prof. Dr. Wilhelm F. Maier Berichterstatter: Prof. Dr. Claus-Michael Lehr Prof. Dr. Rolf Hartmann Vorsitz: Prof. Dr. Ingolf Bernhardt Akad. Mitarbeiter: Dr. Matthias Engel To my offspring The important thing is not to stop questioning. Curiosity has its own reason for existing. Albert Einstein Table of Contents Table of Contents 1. Short summary V 2. Kurzzusammenfassung VII 3. General Introduction 1 3.1. Liberation and absorption of drugs after oral application ........... 1 3.1.1. Drug solubility and dissolution ...................... 2 3.1.2. Principles of drug absorption across the intestinal mucosa ..... 4 3.2. Formulation of poorly aqueous soluble drugs by micellar solubilization .. 10 3.3. Solid dispersions and hot melt extrusion ..................... 14 3.3.1. Solid dispersions for pharmaceutical applications ........... 14 3.3.2. Hot melt extrusion ............................. 15 3.4. The novel solubility enhancer Soluplus⃝R ..................... 18 3.5. The Caco-2 cell culture model ........................... 19 3.6. Aims of this thesis .................................. 21 3.6.1. The Caco-2 model as predictive tool for Soluplus⃝R formulations .. 22 3.6.2. Potential inhibition of P-glycoprotein and/or trypsin by Soluplus⃝R . 23 3.6.3. Optimization of Soluplus⃝R formulations ................ 23 4. Soluplus⃝R as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo 25 4.1.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0302163 A1 Sanchez Et Al
    US 20140302163A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0302163 A1 Sanchez et al. (43) Pub. Date: Oct. 9, 2014 (54) WATER WITH IMPROVED TRANSDERMAL A613 L/714 (2006.01) AND CELLULAR DELIVERY PROPERTIES A 6LX3/59 (2006.01) AND METHODS OF MANUFACTURE AND A 6LX3/593 (2006.01) USE THEREOF A2.3L 2/52 (2006.01) A63/94 (2006.01) (71) Applicant: Subtech Industries, LLC, Stuart, FL (52) U.S. Cl. (US) CPC. A23L I/293 (2013.01); A23L 2/52 (2013.01); C02F I/30 (2013.01); A61 K33/00 (2013.01); (72) Inventors: David Sanchez, Port Saint Lucie, FL A6 IK3I/194 (2013.01); A61 K3I/714 (US); Len Deweerdt, Port Saint Lucie, (2013.01); A61 K3I/519 (2013.01); A61 K FL (US) 31/593 (2013.01); A61K 36/02 (2013.01) USPC ................. 424/600; 426/2: 426/66; 210/251: (73) Assignee: Subtech Industries, LLC, Stuart, FL 210/198.1; 210/201; 210/202: 514/569; 514/52: (US) 424/195.17; 514/789 (21) Appl. No.: 14/214,945 (57) ABSTRACT 1-1. A process for preparing conventional water sources for pro (22) Filed: Mar 16, 2014 viding “ideal state' cellular wellness benefits via topical Related U.S. Application Data hydrationabsorption. and The natural invention’s transdermal, process considersepithelial preconditioned O epicellular (60) Provisional application No. 61/788,206, filed on Mar. water sources that have removed solids, dissolved solids, 15, 2013. contaminants—both organic and inorganic and Subsequently the method purifies the water respective of removing patho Publication Classification gens, and structures the water for cellular uptake in the form of vicinal grade water, with improved characteristics of ideal (51) Int.
    [Show full text]
  • Nutraceutical Potential of Carica Papaya in Metabolic Syndrome
    nutrients Review Nutraceutical Potential of Carica papaya in Metabolic Syndrome Lidiani F. Santana 1, Aline C. Inada 1 , Bruna Larissa Spontoni do Espirito Santo 1, Wander F. O. Filiú 2, Arnildo Pott 3, Flávio M. Alves 3 , Rita de Cássia A. Guimarães 1, Karine de Cássia Freitas 1,* and Priscila A. Hiane 1 1 Graduate Program in Health and Development in the Central-West Region of Brazil, Federal University of Mato Grosso do Sul-UFMS, MS 79079-900 Campo Grande, Brazil 2 Faculdade de Ciências Farmacêuticas, Alimentos e Nutrição, Federal University of Mato Grosso do Sul-UFMS, MS 79079-900 Campo Grande, Brazil 3 Institute of Biosciences, Federal University of Mato Grosso do Sul-UFMS, MS 79079-900 Campo Grande, Brazil * Correspondence: kcfreitas@gmail.com; Tel.: +55-67-3345-7445 Received: 21 June 2019; Accepted: 10 July 2019; Published: 16 July 2019 Abstract: Carica papaya L. is a well-known fruit worldwide, and its highest production occurs in tropical and subtropical regions. The pulp contains vitamins A, C, and E, B complex vitamins, such as pantothenic acid and folate, and minerals, such as magnesium and potassium, as well as food fibers. Phenolic compounds, such as benzyl isothiocyanate, glucosinolates, tocopherols (α and δ), β-cryptoxanthin, β-carotene and carotenoids, are found in the seeds. The oil extracted from the seed principally presents oleic fatty acid followed by palmitic, linoleic and stearic acids, whereas the leaves have high contents of food fibers and polyphenolic compounds, flavonoids, saponins, pro-anthocyanins, tocopherol, and benzyl isothiocyanate. Studies demonstrated that the nutrients present in its composition have beneficial effects on the cardiovascular system, protecting it against cardiovascular illnesses and preventing harm caused by free radicals.
    [Show full text]
  • (Lichtenstein, Ebmeyer Et Al
    Electronic Supplementary Material (ESI) for Food & Function. This journal is © The Royal Society of Chemistry 2015 Supplementary Data Relevant pH and lipase for in vitro models of gastric digestion Laura Samsa,b, Julie Paume b, Jacqueline Giallo b and Frédéric Carrièrea* a CNRS, Aix Marseille Université, Enzymologie Interfaciale et Physiologie de la Lipolyse UMR7282, 31 Chemin Joseph Aiguier, 13402 Marseille Cedex 20, France b GERME S.A., Technopôle Marseille Provence Château-Gombert, ZAC la Baronne,12 Rue Marc Donadille, 13013 Marseille List of the 340 articles with “in vitro digestion” in their title, used for statistics on in vitro digestion models: Aarak, K., B. Kirkhus, et al. (2013). "Release of EPA and DHA from salmon oil–a comparison of in vitro digestion with human and porcine gastrointestinal enzymes." British Journal of Nutrition 110(08): 1402-1410. Aarak, K. E., B. Kirkhus, et al. (2014). "Effect of broccoli phytochemical extract on release of fatty acids from salmon muscle and salmon oil during in vitro digestion." Food & function 5(9): 2331-2337. Aarak, K. E., N. M. Rigby, et al. (2013). "The impact of meal composition on the release of fatty acids from salmon during in vitro gastrointestinal digestion." Food & function 4(12): 1819-1826. Abdalla, A., S. Klein, et al. (2008). "A new self-emulsifying drug delivery system (SEDDS) for poorly soluble drugs: characterization, dissolution, in vitro digestion and incorporation into solid pellets." European Journal of Pharmaceutical Sciences 35(5): 457-464. Aditya, N., M. Shim, et al. (2013). "Curcumin and genistein coloaded nanostructured lipid carriers: in vitro digestion and antiprostate cancer activity." Journal of agricultural and food chemistry 61(8): 1878-1883.
    [Show full text]
  • Cumulative Cross Index to Iarc Monographs
    PERSONAL HABITS AND INDOOR COMBUSTIONS volume 100 e A review of humAn cArcinogens This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 29 September-6 October 2009 LYON, FRANCE - 2012 iArc monogrAphs on the evAluAtion of cArcinogenic risks to humAns CUMULATIVE CROSS INDEX TO IARC MONOGRAPHS The volume, page and year of publication are given. References to corrigenda are given in parentheses. A A-α-C .............................................................40, 245 (1986); Suppl. 7, 56 (1987) Acenaphthene ........................................................................92, 35 (2010) Acepyrene ............................................................................92, 35 (2010) Acetaldehyde ........................36, 101 (1985) (corr. 42, 263); Suppl. 7, 77 (1987); 71, 319 (1999) Acetaldehyde associated with the consumption of alcoholic beverages ..............100E, 377 (2012) Acetaldehyde formylmethylhydrazone (see Gyromitrin) Acetamide .................................... 7, 197 (1974); Suppl. 7, 56, 389 (1987); 71, 1211 (1999) Acetaminophen (see Paracetamol) Aciclovir ..............................................................................76, 47 (2000) Acid mists (see Sulfuric acid and other strong inorganic acids, occupational exposures to mists and vapours from) Acridine orange ...................................................16, 145 (1978); Suppl. 7, 56 (1987) Acriflavinium chloride ..............................................13,
    [Show full text]
  • YMC HPLC Columns Applications Notebook
    WA30000 HPLC Columns Applications Notebook Table of Contents Click on the items below to go directly to that section of the notebook. To Start a new search, click on Table of Contents Bookmark to the left YMC™ HPLC Column Quality Assurance............................................................2 Guide to YMC™ Part Numbering System ...........................................................3 YMC™ Column Selection Guide ....................................................................4-7 HPLC Troubleshooting and Reference Guide..................................................8-14 List of Applications..................................................................................15-20 1. Vitamins .....................................................................................21 2. Carbohydrates ............................................................................32 3. Nucleic Acids .............................................................................43 4. Amino Acids, Peptides, Proteins......................................................48 5. Organic Acids, Fatty Acid Derivatives .............................................60 6. Food Additives ............................................................................62 7. Natural Products ..........................................................................68 8. Steroids......................................................................................77 9. Drugs, Metabolites .......................................................................87
    [Show full text]
  • Kaempferol As a Dietary Anti-Inflammatory Agent
    molecules Review Kaempferol as a Dietary Anti-Inflammatory Agent: Current Therapeutic Standing Waqas Alam 1, Haroon Khan 1,* , Muhammad Ajmal Shah 2 , Omar Cauli 3 and Luciano Saso 4,* 1 Department of Pharmacy, Abdul Wali Khan University Mardan, Mardan 23200, Pakistan; waqasalamyousafzai@gmail.com 2 Department of Pharmacognosy, Faculty of Pharmaceutical Sciences, Government College University, Faisalabad 38000, Pakistan; ajmalshah@gcuf.edu.pk 3 Department of Nursing, University of Valencia, 46010 Valencia, Spain; omar.cauli@uv.es 4 Department of Physiology and Pharmacology “Vittorio Erspamer”, Sapienza University, P.le Aldo Moro 5, 00185 Rome, Italy * Correspondence: hkdr2006@gmail.com(H.K.); luciano.saso@uniroma1.it (L.S.) Academic Editor: Derek J. McPhee Received: 19 July 2020; Accepted: 19 August 2020; Published: 7 September 2020 Abstract: Inflammation is a physiological response to different pathological, cellular or vascular damages due to physical, chemical or mechanical trauma. It is characterized by pain, redness, heat and swelling. Current natural drugs are carefully chosen as a novel therapeutic strategy for the management of inflammatory diseases. Different phytochemical constituents are present in natural products. These phytochemicals have high efficacy both in vivo and in vitro. Among them, flavonoids occur in many foods, vegetables and herbal medicines and are considered as the most active constituent, having the ability to attenuate inflammation. Kaempferol is a polyphenol that is richly found in fruits, vegetables and herbal medicines. It is also found in plant-derived beverages. Kaempferol is used in the management of various ailments but there is no available review article that can summarize all the natural sources and biological activities specifically focusing on the anti-inflammatory effect of kaempferol.
    [Show full text]
  • Recent Progress Regarding Kaempferol for the Treatment of Various Diseases (Review)
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 18: 2759-2776, 2019 Recent progress regarding kaempferol for the treatment of various diseases (Review) JIE REN1,2*, YIFEI LU1,2*, YANHONG QIAN1,2, BOZHOU CHEN1,2, TAO WU1,2 and GUANG JI2 1Center of Chinese Medical Therapy and Systems Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203; 2Institute of Digestive Disease, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, P.R. China Received March 3, 2019; Accepted July 16, 2019 DOI: 10.3892/etm.2019.7886 Abstract. Kaempferol, also known as kaempferol-3 or 4. Application of KP in liver and metabolic diseases kaempferide, is a flavonoid compound that naturally occurs 5. KP protects the vascular endothelium in tea, as well as numerous common vegetables and fruits, 6. KP protects heart function including beans, broccoli, cabbage, gooseberries, grapes, 7. KP protects the cranial nerve kale, strawberries, tomatoes, citrus fruits, brussel sprouts, 8. KP for fibroproliferative disorders apples and grapefruit. The present review mainly summarizes 9. Conclusion the application of kaempferol in treating diseases and the underlying mechanisms that are currently being studied. Due to its anti‑inflammatory properties, it may be used to treat 1. Introduction numerous acute and chronic inflammation‑induced diseases, including intervertebral disc degeneration and colitis, as Kaempferol (KP; chemical name, 3,5,7‑trihydroxy‑2‑ well as post‑menopausal bone loss and acute lung injury. In (4‑hydroxyphenyl)‑4H‑1‑benzopyran‑4‑one; also known as addition, it has beneficial effects against cancer, liver injury, kaempferol‑3, kaempferide or kaempferol flavonol) is a type of obesity and diabetes, inhibits vascular endothelial inflamma- flavonoid.
    [Show full text]
  • SARS-Cov-2: Repurposed Drugs and Novel Therapeutic Approaches—Insights Into Chemical Structure—Biological Activity and Toxicological Screening
    Journal of Clinical Medicine Review SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches—Insights into Chemical Structure—Biological Activity and Toxicological Screening 1, 2,3, 1, 1, Cristina Adriana Dehelean y, Voichita Lazureanu y, Dorina Coricovac * , Marius Mioc *, Roxana Oancea 4, Iasmina Marcovici 1, Iulia Pinzaru 1 , Codruta Soica 1, Aristidis M. Tsatsakis 5 and Octavian Cretu 2 1 Faculty of Pharmacy, “Victor Babes” University of Medicine and Pharmacy, 2nd Eftimie Murgu Sq., 300041 Timisoara, Romania; cadehelean@umft.ro (C.A.D.); iasminamarcovici@yahoo.com (I.M.); iuliapinzaru@umft.ro (I.P.); codrutasoica@umft.ro (C.S.) 2 Faculty of Medicine, “Victor Babes” University of Medicine and Pharmacy, 2nd Eftimie Murgu Sq., 300041 Timisoara, Romania; lazureanu.voichita@umft.ro (V.L.); tavicretu@yahoo.com (O.C.) 3 “Dr. Victor Babes” Clinical Hospital for Infectious Diseases and Pneumophthisiology, 300310 Timisoara, Romania 4 Faculty of Dental Medicine, “Victor Babes” University of Medicine and Pharmacy, 2nd Eftimie Murgu Sq., 300041 Timisoara, Romania; roancea@umft.ro 5 Department of Forensic Sciences and Toxicology, Faculty of Medicine, University of Crete, Heraklion, 71003 Crete, Greece; tsatsaka@uoc.gr * Correspondence: dorinacoricovac@umft.ro (D.C.); marius.mioc@umft.ro (M.M.); Tel.: +4-07-4309-2959 (D.C.); +4-07-5623-6715 (M.M.) Equal contribution as first authors. y Received: 21 May 2020; Accepted: 26 June 2020; Published: 2 July 2020 Abstract: SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) pandemic represents the primary public health concern nowadays, and great efforts are made worldwide for efficient management of this crisis. Considerable scientific progress was recorded regarding SARS-CoV-2 infection in terms of genomic structure, diagnostic tools, viral transmission, mechanism of viral infection, symptomatology, clinical impact, and complications, but these data evolve constantly.
    [Show full text]